Cargando…
A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy
One hundred and seventy-five children with Stage 3 or 4 neuroblastoma who had obtained a good response to conventional therapy were randomly allocated to 13-Cis retinoic acid at a dose of 0.75 mg/kg/day or placebo for up to 4 years. Toxicity was mild but no advantage in event-free survival was shown...
Autores principales: | Kohler, J A, Imeson, J, Ellershaw, C, Lie, S O |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363577/ https://www.ncbi.nlm.nih.gov/pubmed/11027423 http://dx.doi.org/10.1054/bjoc.2000.1425 |
Ejemplares similares
-
Bioavailability and dose-dependent anti-tumour effects of 9-cis retinoic acid on human neuroblastoma xenografts in rat
por: Ponthan, F, et al.
Publicado: (2001) -
Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial
por: Veal, Gareth J., et al.
Publicado: (2021) -
Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – a study of the United Kingdom Children's Cancer Study Group
por: Veal, G J, et al.
Publicado: (2007) -
Comparison of the Effects of 13-cis Retinoic Acid and Melatonin on the Viabilities of SH-SY5Y Neuroblastoma Cell Line
por: Tosun, Murat, et al.
Publicado: (2015) -
Differential and antagonistic effects of 9- cis -retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro
por: Pettersson, F, et al.
Publicado: (2000)